[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Immunovia, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100654889","observational-registry-evaluating-the-clinical-impact-of-the-blood-based-biomarker-test-for-early-stage-pancreatic-ductal-adenocarcinoma-100654889",false,"NCT07805681","Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma","A Multicenter Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test, PancreaSure, for Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC) Detection in High-Risk Surveillance Program","ASSURE","Inclusion Criteria:\n\n* Able to provide informed written consent and complete the survey in English or Spanish\n* \\>45 years of age\n* PancreaSure ordered as part of routine clinical care.\n* At elevated risk for PDAC or is deemed appropriate for PDAC early detection testing based on:\n\n  * Family history in ≥ 2 first-degree relatives, or\n  * Known pathogenic germline mutation (BRCA1\u002F2, CDKN2A, PALB2, ATM, STK11, PRSS1), or\n  * Pancreatic cystic lesion, or\n  * New-onset diabetes with additional risk factors, or\n  * Clinician discretion\n\nExclusion Criteria:\n\n* Prior diagnosis of PDAC or other active malignancy within 3 years (except non-melanoma skin cancer).\n* Participation in interventional investigational studies that may bias test use.\n* Inability or unwillingness to comply with follow-up schedule.","ALL","45 Years",{"count":20,"type":21},400,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic ductal adenocarcinoma. The main question it aims to answer is, does surveillance management and intent change following the return of PancreaSure binary results.",[26,27,28,29],"PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer Stage I","Pancreatic Cancer Stage II","Cancer Diagnosis",[31,32,33,34,27,28,35,36],"Pancreatic Cancer Diagnosis","Pancreatic Cancer","PDAC","Early Detection","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer Detection","NOT_YET_RECRUITING","2026-09-01",{"date":40,"type":41},"2026-09-04","ACTUAL",{"date":43,"type":21},"2026-09",{"date":45,"type":21},"2029-04",{"name":47,"class":48},"Immunovia, Inc.","INDUSTRY",""]